a phase ii study of i-sabr in early or recurrent nsclc
Published 1 year ago • 124 plays • Length 1:49Download video MP4
Download video MP3
Similar videos
-
0:51
assessing i-sabr in early or recurrent non-small cell lung cancer
-
1:08
the future of i-sabr in lung cancer
-
1:00
combining sabr and immunotherapies for nsclc
-
1:51
outcomes of i-sabr in lung cancer
-
0:37
stable-mates: sublobar resection vs sabr in high-risk patients with stage i nsclc
-
2:07
phase i/ii arros-1 study of zidesamtinib in ros1 fusion-positive solid tumors
-
6:06
why i stopped taking low dose naltrexone (ldn)
-
24:20
how to treat early stage non-small cell lung cancer
-
4:28
living well with stage 4 lung cancer
-
1:13
phase ii study of durvalumab for patients with nsclc
-
3:01
phase ii codebreak 100 trial of sotorasib in advanced nsclc
-
2:24
overall survival in the phase ii codebreak 100 trial in nsclc
-
10:19
long-term follow-up of af-001jp: a phase i/ii study of alectinib in alk-positive nsclc
-
1:38
moving forward: targeted therapies in early-stage lung cancer
-
0:47
combining radiotherapy with novel agents in nsclc
-
5:04
sport study: second primary lung cancer
-
1:53
assessing targeted therapies in early stage nsclc
-
41:23
multimodal management of early-stage nsclc: egfr-targeted therapy in perioperative settings
-
4:30
pet-boost study in nsclc
-
1:22
real-world dfs as a predictor of os in resected early-stage non-small cell lung cancer
-
1:00:53
drs. sepesi & cascone discuss egfr-targeted therapy in early-stage nsclc: https://bit.ly/3ozllfo
-
59:19
precision oncology in early-stage lung cancer, with adjuvant egfr-targeted therapy leading the way